Clinical trial
Bortezomib in Treating Children With Advanced Solid Tumors
NCT00021216 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00021216 |
|---|---|
| Title | Bortezomib in Treating Children With Advanced Solid Tumors |
| Official title | A Phase I Study Of PS-341 In Pediatric Patients With Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | bortezomib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 36 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: